Compare

BPC-157 Stable vs CDP-Choline

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

BPC-157 Stable

669 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 63% · Mixed 20% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
24
Digestive comfort
58
Skin appearance
152
Appetite control
29
Energy
126

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
120
Flushing
138
Headache
117
GI discomfort
25
Dizziness
126

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 400–600 mcg

Reports span 50–1000 mcg

50–100
6
100–200
10
200–400
16
400–600
17
600–1000
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing33stacking41side effects29bpc-157 stable27

How repeat users are trending

Among repeat reporters, 58% said they felt similar to their last entry, 43% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 17 days · Based on 147 repeat reporters

CDP-Choline

208 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 52% · Mixed 36% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
159
Focus
52
Sleep quality
152
Lean mass
119
Joint comfort
115

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
75
Nausea
132
Water retention
117
Appetite loss
115
Injection site reaction
114

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.1–0.2 mg

Reports span 0.01–2 mg

0.01–0.025 mg
8
0.025–0.05 mg
17
0.05–0.1 mg
25
0.1–0.2 mg
28
0.2–0.4 mg
19
0.4–0.6 mg
11
0.6–1 mg
8
1–2 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing12stacking25side effects18cdp-choline16

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 15 days · Based on 46 repeat reporters

Sources (8)

Published sources linked on the BPC-157 Stable and CDP-Choline wiki pages.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  3. PubMed

    Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

    Seiwerth S, Milavic M, Vukojevic J, et al. Frontiers in pharmacology. 2021

    Source
    Wiki study page →
  4. PubMed

    Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy

    Sikiric P, Drmic D, Sever M, et al. Current pharmaceutical design. 2020

    Source
    Wiki study page →
  5. PubMed

    Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)

    Davalos A, Alvarez-Sabin J, Castillo J, et al. Lancet. 2012

    Source
    Wiki study page →
  6. PubMed

    Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT)

    Zafonte RD, Bagiella E, Ansel BM, et al. JAMA. 2012

    Source
    Wiki study page →
  7. ClinicalTrials.gov

    International Citicoline Trial on Acute Stroke (ICTUS) (NCT00331890)

    ClinicalTrials.gov. Clinical trial registry. 2006

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    Citicoline Brain Injury Treatment Trial (COBRIT) (NCT00545662)

    ClinicalTrials.gov. Clinical trial registry. 2007

    Source
    Wiki study page →